Page 26 - GPD-4-1

Gene & Protein in Disease Gene fusions and chimeric RNAs

46. Krause M, Hirsh D. A trans-spliced leader sequence on actin doi: 10.1002/gcc.22942
mRNA in C. elegans. Cell. 1987;49:753-761.
58. Torre LA, Bray F, Siegel RL, Ferlay L, Lortet‐Tieulent J,
doi: 10.1016/0092-8674(87)90613-1 Jemal A. Global cancer statistics, 2012. CA Cancer J Clin.
2015;65:87-108.
47. Nilsen TW. Evolutionary origin of SL-addition trans-
splicing: Still an enigma. Trends Genet. 2001;17:678-680. doi: 10.3322/caac.21262
doi: 10.1016/s0168-9525(01)02499-4 59. Zhang H, Lin W, Kannan K, et al. Aberrant chimeric RNA
48. Gao Q, Liang WW, Foltz SM, et al. Driver fusions and their GOLM1-MAK10 encoding a secreted fusion protein as a
implications in the development and treatment of human molecular signature for human esophageal squamous cell
cancers. Cell Rep. 2018;23:227-238.e223. carcinoma. Oncotarget. 2013;4:2135.
doi: 10.1016/j.celrep.2018.03.050 doi: 10.18632/oncotarget.1465
49. Nowell PC, Hungerford DA. Chromosome studies in human 60. Lin Y, Dong H, Deng W, et al. Evaluation of salivary exosomal
leukemia. II. Chronic granulocytic leukemia. J Natl Cancer chimeric GOLM1-NAA35 RNA as a potential biomarker in
Inst. 1961;27:1013-1035. esophageal carcinoma. Clin Cancer Res. 2019;25:3035-3045.
50. Priedigkeit N, Golub T. Potentially Targetable Fusion RNAs doi: 10.1158/1078-0432.CCR-18-3169
May Be More Common in Metastatic Breast Cancer Than 61. Wang L, Xiong X, Yao Z, et al. Chimeric RNA ASTN2-
Previously Realized. Massachusetts: Dana-Farber Cancer PAPPAas aggravates tumor progression and metastasis in
Institute; 2023. human esophageal cancer. Cancer Lett. 2021;501:1-11.
51. Metellus P, Camilla C, Bialecki E, et al. The landscape of doi: 10.1016/j.canlet.2020.10.052
cancer-associated transcript fusions in adult brain tumors:
A longitudinal assessment in 140 patients with cerebral 62. Luo Y, Du L, Yao Z, et al. Generation and application of
gliomas and brain metastases. Front Oncol. 2024;14:1382394. inducible chimeric RNA ASTN2-PAPPAas knockin mouse
model. Cells. 2022;11:277.
doi: 10.3389/fonc.2024.1382394
doi: 10.3390/cells11020277
52. Tong Y, Su X, Rouse W, et al. Transcriptome-wide, unbiased
profiling of ribonuclease targeting chimeras. J Am Chem Soc. 63. Blidner RA, Haynes BC, Hyter S, et al. Design, optimization,
2024;146:21525-21534. and multisite evaluation of a targeted next-generation
sequencing assay system for chimeric RNAs from gene
doi: 10.1021/jacs.4c04717 fusions and exon-skipping events in non-small cell lung
53. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal cancer. J Mol Diagn. 2019;21:352-365.
A. Global cancer statistics 2018: GLOBOCAN estimates of doi: 10.1016/j.jmoldx.2018.10.003.
incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin. 2018;68:394-424. 64. Gow CH, Liu YN, Li HY, et al. Oncogenic function of a
KIF5B-MET fusion variant in non-small cell lung cancer.
doi: 10.3322/caac.21492 Neoplasia. 2018;20:838-847.
54. Qin F, Zhang Y, Liu J, Li H. SLC45A3-ELK4 functions as a doi: 10.1016/j.neo.2018.06.007
long non-coding chimeric RNA. Cancer Lett. 2017;404:53-
61. 65. Chen HF, Wang WX, Xu CW, et al. A novel SOS1-ALK fusion
variant in a patient with metastatic lung adenocarcinoma
doi: 10.1016/j.canlet.2017.07.007
and a remarkable response to crizotinib. Lung Cancer.
55. Zhou F, Gao S, Han D, et al. TMPRSS2-ERG activates 2020;142:59-62.
NO-cGMP signaling in prostate cancer cells. Oncogene. doi: 10.1016/j.lungcan.2020.02.012
2019;38:4397-4411.
66. Izumi H, Matsumoto S, Liu J, et al. The CLIP1-LTK fusion
doi: 10.1038/s41388-019-0730-9
is an oncogenic driver in non‐small‐cell lung cancer. Nature.
56. Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, et 2021;600:319-323.
al. Pseudogene associated recurrent gene fusion in prostate doi: 10.1038/s41586-021-04135-5
cancer. Neoplasia. 2019;21:989-1002.
67. Kitahara CM, Sosa JA. The changing incidence of thyroid
doi: 10.1016/j.neo.2019.07.010
cancer. Nat Rev Endocrinol. 2016;12:646-653.
57. Ptáková N, Martínek P, Holubec L, et al. Identification doi: 10.1038/nrendo.2016.110
of tumors with NRG1 rearrangement, including a novel
putative pathogenic UNC5D‐NRG1 gene fusion in prostate 68. Seib CD, Sosa JS. Evolving understanding of the
cancer by data‐drilling a de‐identified tumor database. epidemiology of thyroid cancer. Endocrinol Metab Clin.
Genes Chromosomes Cancer. 2021;60:474-481. 2019;48:23-35.

Volume 4 Issue 1 (2025) 15 doi: 10.36922/gpd.3641